Cargando…

EZH2 Inhibition and Cisplatin as a Combination Anticancer Therapy: An Overview of Preclinical Studies

SIMPLE SUMMARY: Cisplatin is a chemotherapy drug widely used in the treatment of different cancer types. However, cisplatin displays a high range of toxicity and its use usually leads to resistance. Therefore, combination therapies that include cisplatin are explored to alleviate the problems that a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samaržija, Ivana, Tomljanović, Marko, Novak Kujundžić, Renata, Trošelj, Koraljka Gall
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561994/ https://www.ncbi.nlm.nih.gov/pubmed/36230683 http://dx.doi.org/10.3390/cancers14194761

Ejemplares similares

Implementing Curcumin in Translational Oncology Research
por: Trošelj, Koraljka Gall, et al.
Publicado: (2020)

Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background
por: Gall Trošelj, Koraljka, et al.
Publicado: (2016)

Curcumin and its Potential for Systemic Targeting of Inflamm-Aging and Metabolic Reprogramming in Cancer
por: Kujundžić, Renata Novak, et al.
Publicado: (2019)

Cell-Type Specific Metabolic Response of Cancer Cells to Curcumin
por: Mojzeš, Anamarija, et al.
Publicado: (2020)

Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer
por: Novak Kujundžić, Renata, et al.
Publicado: (2021)

Prognostic Significance of Amino Acid Metabolism-Related Genes in Prostate Cancer Retrieved by Machine Learning
por: Samaržija, Ivana, et al.
Publicado: (2023)

Nutritional Stress in Head and Neck Cancer Originating Cell Lines: The Sensitivity of the NRF2-NQO1 Axis
por: Milković, Lidija, et al.
Publicado: (2019)

Association of Oxidative-Stress-Related Gene Polymorphisms with Pain-Related Temporomandibular Disorders and Oral Behavioural Habits
por: Vrbanović, Ema, et al.
Publicado: (2023)

Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future
por: Pouliquen, Daniel L., et al.
Publicado: (2023)

Gene Expression Profiles – What the Clinician Needs to Know
por: Gall-Troselj, Koraljka
Publicado: (2005)

Harris RJ, Korolchuk VI, eds. Biochemistry and Cell Biology of Aging: Part I Biomedical Science: Subcellular Biochemistry; Springer; e-book 531 pages, 2018; ISBN 978-981-13-2834-3; eISBN 978-981-13-2835-0
por: Gall Trošelj, Koraljka
Publicado: (2020)

Oxidative Stress and Cancer Heterogeneity Orchestrate NRF2 Roles Relevant for Therapy Response
por: Gall Trošelj, Koraljka, et al.
Publicado: (2022)

Editorial: Curcuminoids: their pleiotropism against hallmarks of cancers
por: Pouliquen, Daniel L., et al.
Publicado: (2023)

Even stressed cells are individuals: second messengers of free radicals in pathophysiology of cancer
por: Jaganjac, Morana, et al.
Publicado: (2012)

Expression of nm23-H1 and COX-2 in thyroid papillary carcinoma and microcarcinoma
por: Perisa, Marija Milkovic, et al.
Publicado: (2017)

1,4-Dihydropyridine Derivatives: Dihydronicotinamide Analogues—Model Compounds Targeting Oxidative Stress
por: Velena, Astrida, et al.
Publicado: (2016)

COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?
por: Novak Kujundžić, Renata
Publicado: (2022)

Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients
por: Grbesa, Ivana, et al.
Publicado: (2015)

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2016)

Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2017)

EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers
por: Papale, Marco, et al.
Publicado: (2018)

Overview of Nanoparticle-Based Approaches for the Combination of Photodynamic Therapy (PDT) and Chemotherapy at the Preclinical Stage
por: Menilli, Luca, et al.
Publicado: (2022)

Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer
por: Kim, Woojin, et al.
Publicado: (2013)

Combination Chemotherapy with Selected Polyphenols in Preclinical and Clinical Studies—An Update Overview
por: Jakobušić Brala, Cvijeta, et al.
Publicado: (2023)

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
por: Ciarapica, Roberta, et al.
Publicado: (2014)

Post-Translational Modifications That Drive Prostate Cancer Progression
por: Samaržija, Ivana
Publicado: (2021)

Site-Specific and Common Prostate Cancer Metastasis Genes as Suggested by Meta-Analysis of Gene Expression Data
por: Samaržija, Ivana
Publicado: (2021)

LINC-PINT suppresses cisplatin resistance in gastric cancer by inhibiting autophagy activation via epigenetic silencing of ATG5 by EZH2
por: Zhang, Cheng, et al.
Publicado: (2022)

Targeting Glioma Stem Cells through Combined BMI1 and EZH2 Inhibition
por: Jin, Xun, et al.
Publicado: (2017)

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
por: Zhang, Xi, et al.
Publicado: (2022)

Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2
por: Zeng, Taohui, et al.
Publicado: (2021)

TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma
por: Zhang, Wei, et al.
Publicado: (2020)

Transportan 10 improves the anticancer activity of cisplatin
por: Izabela, Rusiecka, et al.
Publicado: (2016)

Antiviral and Anticancer Activity of Cisplatin Derivatives of Tilorone
por: Roner, Michael R., et al.
Publicado: (2008)

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy
por: Jacobs, Julie, et al.
Publicado: (2017)

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
por: Ott, Patrick A., et al.
Publicado: (2015)

Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro
por: XU, XIAO-MAN, et al.
Publicado: (2013)

Methylene blue in anticancer photodynamic therapy: systematic review of preclinical studies
por: Taldaev, Amir, et al.
Publicado: (2023)

EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
por: Dou, Dongwei, et al.
Publicado: (2019)

EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin
por: Chen, Si-qi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_itun07mt7rbq9kqouuf65jn8ot